Original articles

Liposclerosing myxofibrous tumor: clinicopathologic analysis of 10 cases and review of literature

Expand
  • Department of Pathology of Tenth People's Hospital, Tongji University, Shanghai 200072, China

Received date: 2019-12-01

  Online published: 2022-07-14

Abstract

Objective: To explore the radiological and clinicopathologic characteristics of liposclerosing myxofibrous tumor (LSMFT). Methods: Ten patients diagnosed with LSMFT were enrolled during May 2015 to 2019 in our hospital, and the data including the manifestations, imaging and pathological characteristics were studied retrospectively, and related literatures were reviewed. Results: There were 7 male and 3 female in 10 cases and the average age of onset was 49 years (22-68). All cases showed non-specific clinical symptoms, in which 7 cases complained local pain in lower limb and swollen joint and 2 cases had walking difficulty, while 3 cases didn't show any symptoms. As consistent with literatures, most lesions (8/10) located in the proximal femur or the intertrochanteric region, and 2 lesions were in the proximal tibia. The CT and X-ray images showed a geographic osteolytic lesion with intramedullary eccentric shape or along femur longitudinal axis. The lesions had clear edges, nonhomogeneous density or sclerotic margin. MRI showed the lesions had relatively homogeneous signal on T1WI, and heterogeneously high signal intensity on T2WI with fat suppression. Microscopically, LSMFT was characterized with diversely histologic pattern. The myxofibrous areas, bone trabeculae similar to fibrous dysplasia (FD) and irregular calcification were found in all cases (10/10), and lipomatous areas, Pagetoid bone, xanthoma cells and cyst formation were showed in 7/10, 6/10, 2/10, 1/10 cases, respectively. All patients were treated with curettage and no recurrence were reported during 1-60 month follow-up. Conclusions: LSMFT is a rare benign fibro-osseous lesion with unique radiological features and multiple pathological structures,characterized with myxofibrous areas, irregular calcification and bone trabecula similar to FD. LSMFT should be distinguished from FD and bone infarction.

Cite this article

JIN Jiaoying, JIANG Xiao, XU Ang, ZHANG Changbao, LI Qianyu . Liposclerosing myxofibrous tumor: clinicopathologic analysis of 10 cases and review of literature[J]. Journal of Diagnostics Concepts & Practice, 2020 , 19(06) : 577 -582 . DOI: 10.16150/j.1671-2870.2020.06.006

References

[1] Ragsdale BD. Polymorphic fibro-osseous lesions of bone: an almost site-specific diagnostic problem of the proximal femur[J]. Hum Pathol, 1993, 24(5):505-512.
[2] Kransdorf MJ, Murphey MD, Sweet DE. Liposclerosing myxofibrous tumor: a radiologic-pathologic-distinct fi-broosseous lesion of bone with a marked predilection for the intertrochanteric region of the femur[J]. Radiology, 1999, 212(3):693-698.
[3] 李俊, 谢乐, 彭加友, 等. 骨脂肪硬化性黏液纤维性肿瘤的影像表现与鉴别[J]. 中国医学计算机成像杂志, 2018, 24(4):321-325.
[4] Deel C, Hassell L. Liposclerosing myxofibrous tumor: a review[J]. Arch Pathol Lab Med, 2016, 140(5):473-476.
[5] 李兰, 张铭, 孙晓淇, 等. 脂肪硬化性黏液纤维性肿瘤与纤维结构不良临床及病理学特征对比分析[J]. 临床与实验病理学杂志, 2019, 35(4):452-454,458.
[6] 周隽, 胡丁君, 蒋智铭, 等. 骨脂肪硬化性黏液纤维性肿瘤临床病理特征分析[J]. 中华病理学杂志, 2016, 45(1):21-24.
[7] Regado ER, Garcia PB, Caruso AC, et al. Liposclerosing myxofibrous tumor: a series of 9 cases and review of the literature[J]. J Orthop, 2016, 13(3):136-139.
[8] Técualt-Gómez R, Atencio-Chan A, Cario-Méndez AG, et al. Bone liposclerosing myxofibrous tumor. Case presentation and literature review[J]. Acta Ortop Mex, 2015, 29(3):191-195.
[9] 卫愉轩, 王永杰, 梁超, 等. 骨脂肪硬化性黏液纤维性肿瘤的临床诊疗分析[J]. 骨科临床与研究杂志, 2019, 4(5):281-285.
[10] Matsuba A, Ogose A, Tokunaga K, et al. Activating Gs alpha mutation at the Arg201 codon in liposclerosing myxofibrous tumor[J]. Hum Pathol, 2003, 34(11):1204-1209.
[11] Rothschild B, Ulrich-Bochsler S, Ruhle F. When is a geode not a geode: when LSMFT?[J]. Rheumatology (Oxford), 2001, 40(6):706-707.
[12] Murphey MD, Carroll JF, Flemming DJ, et al. From the archives of the AFIP: benign musculoskeletal lipomatous lesions[J]. Radiographics, 2004, 24(5):1433-1466.
[13] Dattilo J, McCarthy EF. Liposclerosing myxofibrous tumor (LSMFT), a study of 33 patients: should it be a distinct entity?[J]. Iowa Orthop J, 2012, 32:35-39.
[14] Campbell RM. Problem injuries in unique conditions of the musculoskeletal system[M]// Rockwood CA, Wilkins KE, Beaty JH. Fractures in children. Philadelphia: Lippincott-Raven, 1996:167-320.
[15] Shi RR, Li XF, Zhang R, et al. GNAS mutational analysis in differentiating fibrous dysplasia and ossifying fibroma of the jaw[J]. Mod Pathol, 2013, 26(8):1023-1031.
[16] Jour G, Oultache A, Sadowska J, et al. GNAS mutations in fibrous dysplasia: a comparative study of standard sequencing and locked nucleic acid PCR sequencing on decalcified and nondecalcified formalin-fixed paraffin-embedded tissues[J]. Appl Immunohistochem Mol Morphol, 2016, 24(9):660-667.
[17] Corsi A, De Maio F, Ippolito E, et al. Monostotic fibrous dysplasia of the proximal femur and liposclerosing myxo-fibrous tumor: which one is which?[J]. J Bone Miner Res, 2006, 21(12):1955-1958.
[18] Beytemür O, Tetikkurt üS, Albay C, et al. Liposclerosing myxofibrous tumor: a rare tumor of proximal femur[J]. Eklem Hastalik Cerrahisi, 2017, 28(3):210-213.
[19] Beytemür O, Tetikkurt üS, Albay C, et al. Telangiectatic osteosarcoma secondary to a liposclerosing myxofibrous tumor: a case report[J]. Eklem Hastalik Cerrahisi, 2017, 28(3):210-213.
[20] Campbell K, Wodajo F. Case report: two-step malignant transformation of a liposclerosing myxofibrous tumor of bone[J]. Clin Orthop Relat Res, 2008, 466(11):2873-2877.
Outlines

/